Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves.
A Treatment Costs $450,000, It Had Better Work
Comment
Show comments
Hide Comments
Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves.
